---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-153471"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:00:33.702921+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verrica amends Torii deal: $8M milestone accelerated, $10M on Japan approval, $40M trial funding

## Summary
- Torii pays $8M milestone in July 2025 for starting global Phase 3 common warts trial of YCANTH.
- Torii to pay $10M cash upon Japanese approval of YCANTH for molluscum, expected by end-2025.
- Torii funds first $40M of trial costs (~90% of budget); Verrica repays via future royalties/transfer price.
- First patient dosing in U.S. Phase 3 common warts trial expected Q4 2025.
- OrbiMed waived going-concern qualification requirement under credit agreement for remainder of 2025.

## SEC filing metadata
- accession: 0001193125-25-153471
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525153471/0001193125-25-153471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525153471/d682251d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-153471
- JSON: https://secwatch.observer/filing/0001193125-25-153471.json
- Plain text: https://secwatch.observer/filing/0001193125-25-153471.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.